PAX5 and diffuse large B-cell lymphoma: Research indicates that in cases of CD20-negative diffuse large B-cell lymphoma (DLBCL), the inclusion of CD79a and PAX5 in the immunohistochemical panel can significantly enhance diagnostic specificity and sensitivity [19].